About the Multiple Myeloma Research Foundation®
The mission of the Multiple Myeloma Research Foundation (MMRF) is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and find a cure. Founded in 1998 by multiple myeloma patient Kathy Giusti and her twin sister Karen Andrews as a 501(c)(3) non-profit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF created the only end-to-end solution in precision medicine, generated the single largest genomic data set in all cancers and continues to disrupt, pioneer and lead new research efforts. The MMRF has raised over $400 million since its inception and directs nearly 90% of the total funds raised to research and related programs.
About Multiple Myeloma
Multiple myeloma is a type of blood cancer that affects the plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infections. These malignant plasma cells then produce abnormal proteins (m protein), which may cause tumors, damage the kidneys, and impair immune system function. In some cases, the malignant cells may cause a single tumor, called a solitary plasmacytoma, but if multiple tumors are formed, then the disease is called multiple myeloma.

Multiple myeloma is the second most common blood cancer, and although it is considered incurable, it is very much a treatable disease thanks to recent advancements in cancer research. Historically, there was little hope for multiple myeloma patients, because multiple myeloma treatment options were incredibly limited. The Multiple Myeloma Research Foundation (MMRF), however, has revolutionized the way multiple myeloma is treated, substantially improving the life expectancy of multiple myeloma patients. Since its inception, the MMRF has helped introduce ten new drugs and through the power of new technology, genomics, and immunology, lives are now being saved.
CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers and advocacy groups. CURE Media Group’s offerings also include its online resource,; live meetings; a resource guide for the newly diagnosed; and the Extraordinary Healer™ national nursing award. CURE Media Group combines science and humanity to make cancer understandable.

CURE magazine, launched in 2002 for cancer patients, survivors and caregivers, has become the largest consumer magazine in the United States focused entirely on cancer. With a circulation of 300,000 individual subscribers account for over 170,000 of that figure with the remainder going to cancer centers and advocacy groups around the country. Since its inception, CURE has expanded to reflect the entire cancer continuum, including supportive care issues and long-term and late effects.

In 2014, Michael J. Hennessy Associates‘ Inc (MJH) acquired CURE MEDIA GROUP. This acquisition joined CURE with MJH‘s acclaimed OncLive® ( platform of resources for the practicing oncologist. OncLive‘s offerings include its website, with the most up-to-date information for professionals in cancer care; the renowned Peer Exchange and OncLive Insights video series; a full suite of monthly and quarterly publications; and the recently launched OncLive News Network, which provides the latest in breaking news on a 24/7 basis. OncLive is also the official communications partner of Physicians‘ Education Resource® (PER®), the educational resource of choice for live and online activities focusing on oncology and hematology.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit
Interested in multiple myeloma updates from CURE®? Sign up for our newsletter!

Multiple Myeloma Research Foundation

View our interviews with climber Chuck Wakefield
Terms & Conditions | Privacy Policy